{"denoms":[{"counts":[{"groupId":"BG000","value":"310"}],"units":"Participants"}],"groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"BG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.1","value":"65.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"241"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Cohort 2 Safety Evaluable Population included all participants who received any amount of study drug."}